Top

BY Scott Merville

Surveying the landscape of T cell presence and activity across the lungs of patients treated for localized non-small cell lung cancer, researchers have found that what matters most are T cells found in normal tissue.

When the tumor and uninvolved normal tissue elsewhere in the lung share high proportions of T cells, the immune response is less focused on the tumor and more distracted by the pursuit of viruses and other inflammatory...

Jianjun Zhang, M.D., Ph.D.

BY Clayton R. Boldt, Ph.D.

Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important...

BY Scott Merville


An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different...

BY Clayton Boldt, Ph. D.

MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. The platform is one of the research engines driving MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives. 

By working closely...

Katy Rezvani, M.D., Ph.D., equips innate immune system natural killer cells with a chimeric antigen receptor that targets B cell malignancies, an approach that’s yielded results in early clinical trials. Her lab is developing CAR NK cells against other cancers.

BY Scott Merville

Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...

BY Clayton Boldt, Ph.D.

Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...

BY Meagan Raeke

Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...

BY Ron Gilmore

The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...

BY Clayton Boldt, Ph.D.

According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...